Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2383-2390

  Bi, Nan ^a   Yang, Ming ^a,b   Zhang, Li ^a,c   Chen, Xiabin ^a   Ji, Wei ^a   Ou, Guangfei ^a   Lin, Dongxin ^a   Wang, Luhua ^a  

^a CANCER HOSPITAL   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DNA;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951018691     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2793     Document Type: Article

References (45)

1. Gandara D, Narayan S, Lara PN, Jr., et al. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 2005;11:5057-62s.
2. Lee CB, Stinchcombe TE, Rosenman JG, et al. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 2006;8:195-202.
3. Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev 2008;27:445-458
4. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996;270:G393-400.
5. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054
6. Tsujii M, DuBois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995;83:493-501.
7. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716 (Pubitemid 28257578)
8. Elder D, Halton D, Hague A, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-1683 (Pubitemid 27444704)
9. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764 (Pubitemid 28405625)
10. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001. (Pubitemid 28521147)
11. Watkins DN, Lenzo JC, Segal A, et al. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999;14:412-418 (Pubitemid 29461310)
12. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005 (Pubitemid 29233213)
13. O'Connor JK, Avent J, Lee RJ, et al. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:1034-1040 (Pubitemid 38314783)
14. Gaffney DK, Holden J, Davis M, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49:1213-1217 (Pubitemid 32294300)
15. Duffy CP, Elliott CJ, O'Connor RA, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250-1259
16. Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6:2513-2520 (Pubitemid 30399223)
17. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998;58:5354-5360 (Pubitemid 28551116)
18. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-1331 (Pubitemid 30152002)
19. Kim SH, Park HS. Genetic markers for differentiating aspirin- hypersensitivity. Yonsei Med J 2006;47:15-21.
20. Zhao D, Xu D, Zhang X, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 2009;136:1659-1668
21. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005;129:565-576 (Pubitemid 41096644)
22. Guo YL, Zhang XM, Tan W, et al. Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics 2007; 17:197-205. (Pubitemid 46668004)
23. Zhao D, Zhang X, Guo Y, et al. Cyclooxygenase-2 Gly587Arg variant is associated with differential enzymatic activity and risk of esophageal squamous-cell carcinoma. Mol Carcinog 2009;48:934-941
24. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006;17:6-70.
25. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004;25:229-235 (Pubitemid 38239806)
26. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-2601 (Pubitemid 41103746)
27. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14:1797-1803
28. Yu D, Zhang X, Liu J, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008; 14:2878-2886
29. Tan W, Wu J, Zhang X, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007;28:1197-1201 (Pubitemid 47064309)
30. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 2007;67:821-845
31. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005. (Pubitemid 32963816)
32. Gaffney DK, Holden J, Zempolich K, et al. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001;24:443-446 (Pubitemid 32959099)
33. Formenti SC, Spicer D, Skinner K, et al. Pre-operative twice weekly paclitaxel and radiation therapy in locally advanced breast cancer (LABC):molecular determinants of pathological response. Proc ASCO 1999;18:75a.
34. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005;48:11-17 (Pubitemid 40380996)
35. Iglesias D, Nejda N, Azcoita MM, et al. Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 2009. Epub ahead of print.
36. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440-443 (Pubitemid 34183896)
37. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001:861-867 (Pubitemid 32708722)
38. Lilenbaum R, Socinski MA, Altorki NK, et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006;24:4825-4832 (Pubitemid 46630908)
39. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 2008;639:89-100. (Pubitemid 47588301)
40. Pan JH, Han JX, Wu JM, et al. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008;75:380-385 (Pubitemid 351685428)
41. Mutter R, Lu B, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158-2165
42. Agarwala A, Fisher W, Bruetman D, et al. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 2008;3:374-379 (Pubitemid 351489477)
43. Schneider BJ, Kalemkerian GP, Kraut MJ, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 2008;3:1454-1459
44. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-cancer and leukemia group B trial 30203. J Clin Oncol 2008;26:848-855 (Pubitemid 351398075)
45. Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008;14:2088-2094 (Pubitemid 351551120)